Download PDF
J Knee Surg 2022; 35(06): 585-596
DOI: 10.1055/s-0042-1743221
Special Focus Section

Management of Primary Aggressive Tumors of the Knee

John R. Martin
1   Department of Orthopaedic Surgery, University of Arizona College of Medicine, Phoenix, Arizona
,
Richard L. Auran 
1   Department of Orthopaedic Surgery, University of Arizona College of Medicine, Phoenix, Arizona
,
Michael D. Duran
2   The Center for Orthopedic Research and Eduction (CORE) Institute, Phoenix, Arizona
,
Amalia M. de Comas
1   Department of Orthopaedic Surgery, University of Arizona College of Medicine, Phoenix, Arizona
2   The Center for Orthopedic Research and Eduction (CORE) Institute, Phoenix, Arizona
,
David J. Jacofsky
2   The Center for Orthopedic Research and Eduction (CORE) Institute, Phoenix, Arizona
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Primary bone sarcomas and aggressive benign bone tumors are relatively rare. It is essential to recognize features that are concerning for these aggressive tumors based on a patient's history, physical exam, and radiographs. Physicians and other health care providers should have a high suspicion for these tumors and promptly refer these patients to orthopaedic oncologists. A multidisciplinary, team-based approach is required to obtain an accurate diagnosis and provide comprehensive care. This review discussed the appropriate work-up, biopsy principles, relevant peri-operative medical management, and surgical treatment options for patients with aggressive primary bone tumors around the knee. Primary bone sarcomas (osteosarcoma and chondrosarcoma) and aggressive benign bone tumors (giant cell tumor, chondroblastoma, and chondromyxoid fibroma) that have a predilection to the distal femur and proximal tibia are the focus of this review.

Keywords

knee joint - aggressive tumors - orthopaedic oncology - benign tumors - malignant bone tumors


Publication History

Received: 02 December 2021

Accepted: 22 December 2021

Article published online:
18 February 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 National Cancer Institute. SEER Cancer Stat Facts: Bone and Joint Cancer. Accessed November 11, 2021. at: https://seer.cancer.gov/statfacts/html/bones.html
    PubMedGoogle Scholar
  • 2 American Cancer Society. Facts and Figures 2021. Atlanta, GA: American Cancer Society; 2021
    Google Scholar
  • 3 Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; (204) 9-24
    PubMedGoogle Scholar
  • 4 Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987; 69 (01) 106-114
    CrossrefPubMedGoogle Scholar
  • 5 Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumor of bone. Am J Clin Oncol 2006; 29 (01) 96-99
    CrossrefPubMedGoogle Scholar
  • 6 Farfalli GL, Slullitel PAI, Muscolo DL, Ayerza MA, Aponte-Tinao LA. What happens to the articular surface after curettage for epiphyseal chondroblastoma? A report on functional results, arthritis, and arthroplasty. Clin Orthop Relat Res 2017; 475 (03) 760-766
    CrossrefPubMedGoogle Scholar
  • 7 Deventer N, Deventer N, Gosheger G. et al. Chondroblastoma: is intralesional curettage with the use of adjuvants a sufficient way of therapy?. J Bone Oncol 2020; 26: 100342
    CrossrefPubMedGoogle Scholar
  • 8 Wilson AJ, Kyriakos M, Ackerman LV. Chondromyxoid fibroma: radiographic appearance in 38 cases and in a review of the literature. Radiology 1991; 179 (02) 513-518
    CrossrefPubMedGoogle Scholar
  • 9 Beggs IG, Stoker DJ. Chondromyxoid fibroma of bone. Clin Radiol 1982; 33 (06) 671-679
    CrossrefPubMedGoogle Scholar
  • 10 Biazzo A, De Paolis M. Multidisciplinary approach to osteosarcoma. Acta Orthop Belg 2016; 82 (04) 690-698
    PubMedGoogle Scholar
  • 11 Jacofsky DJ, Haidukewych GJ. Management of pathologic fractures of the proximal femur: state of the art. J Orthop Trauma 2004; 18 (07) 459-469
    CrossrefPubMedGoogle Scholar
  • 12 Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 2000; 82 (05) 667-674
    CrossrefPubMedGoogle Scholar
  • 13 Clayer M. Many faces of osteosarcoma on plain radiographs. ANZ J Surg 2015; 85 (1-2): 22-26
    CrossrefPubMedGoogle Scholar
  • 14 Ayoub KS, Grimer RJ, Carter SR, Mangham DC, Davies AM, Tillman RM. Clear cell chondrosarcoma of bone. Sarcoma 1999; 3 (02) 115-119
    CrossrefPubMedGoogle Scholar
  • 15 Bjornsson J, Unni KK, Dahlin DC, Beabout JW, Sim FH. Clear cell chondrosarcoma of bone. Observations in 47 cases. Am J Surg Pathol 1984; 8 (03) 223-230
    CrossrefPubMedGoogle Scholar
  • 16 Meazza C, Cefalo G, Massimino M. et al. Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2. Med Oncol 2017; 34 (12) 191
    CrossrefPubMedGoogle Scholar
  • 17 Özer D, Arıkan Y, Gür V, Gök C, Akman YE. Chondroblastoma: an evaluation of the recurrences and functional outcomes following treatment. Acta Orthop Traumatol Turc 2018; 52 (06) 415-418
    CrossrefPubMedGoogle Scholar
  • 18 Aryal A, Kumar VS, Shamim SA, Gamanagatti S, Khan SA. What is the comparative ability of 18F-FDG PET/CT, 99mTc-MDP skeletal scintigraphy, and whole-body MRI as a staging investigation to detect skeletal metastases in patients with osteosarcoma and Ewing sarcoma?. Clin Orthop Relat Res 2021; 479 (08) 1768-1779
    CrossrefPubMedGoogle Scholar
  • 19 Tal AL, Doshi H, Parkar F. et al. The utility of 18FDG PET/CT versus bone scan for identification of bone metastases in a pediatric sarcoma population and a review of the literature. J Pediatr Hematol Oncol 2021; 43 (02) 52-58
    CrossrefPubMedGoogle Scholar
  • 20 Hurley C, McCarville MB, Shulkin BL. et al. Comparison of (18) F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma. Pediatr Blood Cancer 2016; 63 (08) 1381-1386
    CrossrefPubMedGoogle Scholar
  • 21 Lee I, Byun BH, Lim I. et al. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma. Medicine (Baltimore) 2018; 97 (37) e12318
    CrossrefPubMedGoogle Scholar
  • 22 Song H, Jiao Y, Wei W. et al. Can pretreatment 18F-FDG PET tumor texture features predict the outcomes of osteosarcoma treated by neoadjuvant chemotherapy?. Eur Radiol 2019; 29 (07) 3945-3954
    CrossrefPubMedGoogle Scholar
  • 23 Byun BH, Kong CB, Park J. et al. Initial metabolic tumor volume measured by 18F-FDG PET/CT can predict the outcome of osteosarcoma of the extremities. J Nucl Med 2013; 54 (10) 1725-1732
    CrossrefPubMedGoogle Scholar
  • 24 Mankin HJ, Mankin CJ, Simon MA. Members of the Musculoskeletal Tumor Society. The hazards of the biopsy, revisited. J Bone Joint Surg Am 1996; 78 (05) 656-663
    CrossrefPubMedGoogle Scholar
  • 25 Pohlig F, Kirchhoff C, Lenze U. et al. Percutaneous core needle biopsy versus open biopsy in diagnostics of bone and soft tissue sarcoma: a retrospective study. Eur J Med Res 2012; 17: 29
    CrossrefPubMedGoogle Scholar
  • 26 Traina F, Errani C, Toscano A. et al. Current concepts in the biopsy of musculoskeletal tumors. J Bone Joint Surg Am 2015; 97 (01) e7
    CrossrefPubMedGoogle Scholar
  • 27 Bickels J, Jelinek JS, Shmookler BM, Neff RS, Malawer MM. Biopsy of musculoskeletal tumors. Current concepts. Clin Orthop Relat Res 1999; (368) 212-219
    PubMedGoogle Scholar
  • 28 Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Clin Orthop Relat Res 2007; 459: 40-47
    CrossrefPubMedGoogle Scholar
  • 29 Saeter G, Alvegård TA, Elomaa I, Stenwig AE, Holmström T, Solheim OP. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9 (10) 1766-1775
    CrossrefPubMedGoogle Scholar
  • 30 Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106 (05) 1154-1161
    CrossrefPubMedGoogle Scholar
  • 31 Smeland S, Bielack SS, Whelan J. et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 2019; 109 (109) 36-50
    CrossrefPubMedGoogle Scholar
  • 32 Sajadi KR, Heck RK, Neel MD. et al. The incidence and prognosis of osteosarcoma skip metastases. Clin Orthop Relat Res 2004; (426) 92-96
    CrossrefPubMedGoogle Scholar
  • 33 Smeland S, Müller C, Alvegard TA. et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39 (04) 488-494
    CrossrefPubMedGoogle Scholar
  • 34 Marina NM, Smeland S, Bielack SS. et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 2016; 17 (10) 1396-1408
    CrossrefPubMedGoogle Scholar
  • 35 Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am 1990; 72 (05) 643-653
    CrossrefPubMedGoogle Scholar
  • 36 Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res 2002; (397) 53-61
    CrossrefPubMedGoogle Scholar
  • 37 Winkler K, Beron G, Kotz R. et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984; 2 (06) 617-624
    CrossrefPubMedGoogle Scholar
  • 38 Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 2009; 91 (05) 1063-1072
    CrossrefPubMedGoogle Scholar
  • 39 Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977; 40 (02) 818-831
    CrossrefPubMedGoogle Scholar
  • 40 Wang Z, Chen G, Chen X. et al. Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis. J Cancer 2019; 10 (11) 2457-2463
    CrossrefPubMedGoogle Scholar
  • 41 Kamal AF, Husodo K, Prabowo Y, Hutagalung EU. Correlation between survival and tumour characteristics in patients with chondrosarcoma. J Orthop Surg (Hong Kong) 2015; 23 (03) 365-369
    CrossrefPubMedGoogle Scholar
  • 42 Fiorenza F, Abudu A, Grimer RJ. et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 2002; 84 (01) 93-99
    CrossrefPubMedGoogle Scholar
  • 43 Ebeid WA, Badr IT, Mesregah MK, Hasan BZ. Risk factors and oncological outcomes of pulmonary metastasis in patients with giant cell tumor of bone. J Clin Orthop Trauma 2021; 20: 101499
    CrossrefPubMedGoogle Scholar
  • 44 Rodgers WB, Mankin HJ. Metastatic malignant chondroblastoma. Am J Orthop 1996; 25 (12) 846-849
    PubMedGoogle Scholar
  • 45 Link MP, Goorin AM, Miser AW. et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314 (25) 1600-1606
    CrossrefPubMedGoogle Scholar
  • 46 Meyers PA, Heller G, Healey J. et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10 (01) 5-15
    CrossrefPubMedGoogle Scholar
  • 47 Meyers PA, Schwartz CL, Krailo M. et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23 (09) 2004-2011
    CrossrefPubMedGoogle Scholar
  • 48 Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 2010; 21 (Suppl. 07) vii320-vii325
    CrossrefPubMedGoogle Scholar
  • 49 Warr J, Hird AE, DeAngelis C, Giotis A, Ko YJ. Baseline blood work before initiation of chemotherapy: what is safe in the real world?. J Oncol Pract 2013; 9 (05) e182-e185
    CrossrefPubMedGoogle Scholar
  • 50 Kawaguchi S, Sun T, Lin PP, Deavers M, Harun N, Lewis VO. Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?. Clin Orthop Relat Res 2014; 472 (03) 983-989
    CrossrefPubMedGoogle Scholar
  • 51 Hompland I, Ferrari S, Bielack S. et al. Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: results from the European Bone Over 40 Sarcoma Study. Eur J Cancer 2021; 151 (151) 150-158
    CrossrefPubMedGoogle Scholar
  • 52 Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg 2019; 139 (10) 1339-1349
    CrossrefPubMedGoogle Scholar
  • 53 Traub F, Singh J, Dickson BC. et al. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. Eur J Cancer 2016; 59 (59) 1-12
    CrossrefPubMedGoogle Scholar
  • 54 Chawla S, Henshaw R, Seeger L. et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14 (09) 901-908
    CrossrefPubMedGoogle Scholar
  • 55 Errani C, Tsukamoto S, Leone G. et al. Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am 2018; 100 (06) 496-504
    CrossrefPubMedGoogle Scholar
  • 56 De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50 (03) 187-196
    CrossrefPubMedGoogle Scholar
  • 57 Mousa SA. Anti-thrombotics in thrombosis and cancer. Future Oncol 2005; 1 (03) 395-403
    CrossrefPubMedGoogle Scholar
  • 58 Patel AR, Crist MK, Nemitz J, Mayerson JL. Aspirin and compression devices versus low-molecular-weight heparin and PCD for VTE prophylaxis in orthopedic oncology patients. J Surg Oncol 2010; 102 (03) 276-281
    CrossrefPubMedGoogle Scholar
  • 59 Lin PP, Thenappan A, Deavers MT, Lewis VO, Yasko AW. Treatment and prognosis of chondroblastoma. Clin Orthop Relat Res 2005; 438 (438) 103-109
    CrossrefPubMedGoogle Scholar
  • 60 Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res 2004; (424) 221-226
    CrossrefPubMedGoogle Scholar
  • 61 Lewis VO, Wei A, Mendoza T, Primus F, Peabody T, Simon MA. Argon beam coagulation as an adjuvant for local control of giant cell tumor. Clin Orthop Relat Res 2007; 454 (454) 192-197
    CrossrefPubMedGoogle Scholar
  • 62 Malawer MM, Bickels J, Meller I, Buch RG, Henshaw RM, Kollender Y. Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Clin Orthop Relat Res 1999; (359) 176-188
    CrossrefPubMedGoogle Scholar
  • 63 Marcove RC, Weis LD, Vaghaiwalla MR, Pearson R. Cryosurgery in the treatment of giant cell tumors of bone: a report of 52 consecutive cases. Clin Orthop Relat Res 1978; (134) 275-289
    PubMedGoogle Scholar
  • 64 Quint U, Müller RT, Müller G. Characteristics of phenol. Instillation in intralesional tumor excision of chondroblastoma, osteoclastoma and enchondroma. Arch Orthop Trauma Surg 1998; 117 (1-2): 43-46
    PubMedGoogle Scholar
  • 65 Moon MS, Kim SSS, Moon JL, Kim SS, Moon H. Treating giant cell tumours with curettage, electrocautery, burring, phenol irrigation, and cementation. J Orthop Surg (Hong Kong) 2013; 21 (02) 209-212
    CrossrefPubMedGoogle Scholar
  • 66 Nicholson NC, Ramp WK, Kneisl JS, Kaysinger KK. Hydrogen peroxide inhibits giant cell tumor and osteoblast metabolism in vitro. Clin Orthop Relat Res 1998; (347) 250-260
    PubMedGoogle Scholar
  • 67 Omlor GW, Lange J, Streit M. et al. Retrospective analysis of 51 intralesionally treated cases with progressed giant cell tumor of the bone: local adjuvant use of hydrogen peroxide reduces the risk for tumor recurrence. World J Surg Oncol 2019; 17 (01) 73
    CrossrefPubMedGoogle Scholar
  • 68 Lersundi A, Mankin HJ, Mourikis A, Hornicek FJ. Chondromyxoid fibroma: a rarely encountered and puzzling tumor. Clin Orthop Relat Res 2005; 439 (439) 171-175
    CrossrefPubMedGoogle Scholar
  • 69 Zuo D, Zheng L, Sun W, Fu D, Hua Y, Cai Z. Contemporary adjuvant polymethyl methacrylate cementation optimally limits recurrence in primary giant cell tumor of bone patients compared to bone grafting: a systematic review and meta-analysis. World J Surg Oncol 2013; 11: 156
    CrossrefPubMedGoogle Scholar
  • 70 Ramappa AJ, Lee FY, Tang P, Carlson JR, Gebhardt MC, Mankin HJ. Chondroblastoma of bone. J Bone Joint Surg Am 2000; 82 (08) 1140-1145
    CrossrefPubMedGoogle Scholar
  • 71 Ebeid WA, Hasan BZ, Badr IT, Mesregah MK. Functional and oncological outcome after treatment of chondroblastoma with intralesional curettage. J Pediatr Orthop 2019; 39 (04) e312-e317
    CrossrefPubMedGoogle Scholar
  • 72 Sharil A, Nawaz A, Nor Azman M, Zulmi W, Faisham W. Early functional outcome of resection and endoprosthesis replacement for primary tumor around the knee. Malays Orthop J 2013; 7 (01) 30-35
    CrossrefPubMedGoogle Scholar
  • 73 Zhang C, Hu J, Zhu K, Cai T, Ma X. Survival, complications and functional outcomes of cemented megaprostheses for high-grade osteosarcoma around the knee. Int Orthop 2018; 42 (04) 927-938
    CrossrefPubMedGoogle Scholar
  • 74 Jeys LM, Kulkarni A, Grimer RJ, Carter SR, Tillman RM, Abudu A. Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. J Bone Joint Surg Am 2008; 90 (06) 1265-1271
    CrossrefPubMedGoogle Scholar
  • 75 Bickels J, Wittig JC, Kollender Y. et al. Distal femur resection with endoprosthetic reconstruction: a long-term followup study. Clin Orthop Relat Res 2002; (400) 225-235
    CrossrefPubMedGoogle Scholar
  • 76 Song WS, Kong CB, Jeon DG. et al. The impact of amount of bone resection on uncemented prosthesis failure in patients with a distal femoral tumor. J Surg Oncol 2011; 104 (02) 192-197
    CrossrefPubMedGoogle Scholar
  • 77 Schwartz AJ, Kabo JM, Eilber FC, Eilber FR, Eckardt JJ. Cemented distal femoral endoprostheses for musculoskeletal tumor: improved survival of modular versus custom implants. Clin Orthop Relat Res 2010; 468 (08) 2198-2210
    CrossrefPubMedGoogle Scholar
  • 78 Piakong P, Kiatisevi P, Yau R. et al. What is the 10-year survivorship of cemented distal femoral endoprostheses for tumor reconstructions and what radiographic features are associated with survival?. Clin Orthop Relat Res 2020; 478 (11) 2573-2581
    CrossrefPubMedGoogle Scholar
  • 79 Batta V, Coathup MJ, Parratt MT. et al. Uncemented, custom-made, hydroxyapatite-coated collared distal femoral endoprostheses: up to 18 years' follow-up. Bone Joint J 2014; 96-B (02) 263-269
    CrossrefPubMedGoogle Scholar
  • 80 Heisel C, Kinkel S, Bernd L, Ewerbeck V. Megaprostheses for the treatment of malignant bone tumours of the lower limbs. Int Orthop 2006; 30 (06) 452-457
    CrossrefPubMedGoogle Scholar
  • 81 Bus MPA, van de Sande MAJ, Fiocco M, Schaap GR, Bramer JAM, Dijkstra PDS. What are the long-term results of MUTARS® modular endoprostheses for reconstruction of tumor resection of the distal femur and proximal tibia?. Clin Orthop Relat Res 2017; 475 (03) 708-718
    CrossrefPubMedGoogle Scholar
  • 82 Kinkel S, Lehner B, Kleinhans JA, Jakubowitz E, Ewerbeck V, Heisel C. Medium to long-term results after reconstruction of bone defects at the knee with tumor endoprostheses. J Surg Oncol 2010; 101 (02) 166-169
    PubMedGoogle Scholar
  • 83 Myers GJC, Abudu AT, Carter SR, Tillman RM, Grimer RJ. Endoprosthetic replacement of the distal femur for bone tumours: long-term results. J Bone Joint Surg Br 2007; 89 (04) 521-526
    CrossrefPubMedGoogle Scholar
  • 84 Flint MN, Griffin AM, Bell RS, Ferguson PC, Wunder JS. Aseptic loosening is uncommon with uncemented proximal tibia tumor prostheses. Clin Orthop Relat Res 2006; 450 (450) 52-59
    CrossrefPubMedGoogle Scholar
  • 85 Henderson ER, Groundland JS, Pala E. et al. Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am 2011; 93 (05) 418-429
    CrossrefPubMedGoogle Scholar
  • 86 Griffin AM, Parsons JA, Davis AM, Bell RS, Wunder JS. Uncemented tumor endoprostheses at the knee: root causes of failure. Clin Orthop Relat Res 2005; 438 (438) 71-79
    CrossrefPubMedGoogle Scholar
  • 87 Sala M, Taylor M, Tanner KE. Torsional stability of primary total knee replacement tibial prostheses: a biomechanical study in cadaveric bone. J Arthroplasty 1999; 14 (05) 610-615
    CrossrefPubMedGoogle Scholar
  • 88 Frink SJ, Rutledge J, Lewis VO, Lin PP, Yasko AW. Favorable long-term results of prosthetic arthroplasty of the knee for distal femur neoplasms. Clin Orthop Relat Res 2005; 438 (438) 65-70
    CrossrefPubMedGoogle Scholar
  • 89 Lu M, Wang J, Xiao C. et al. Uncemented, curved, short endoprosthesis stem for distal femoral reconstruction: early follow-up outcomes. World J Surg Oncol 2018; 16 (01) 183
    CrossrefPubMedGoogle Scholar
  • 90 Bhangu AA, Kramer MJ, Grimer RJ, O'Donnell RJ. Early distal femoral endoprosthetic survival: cemented stems versus the compress implant. Int Orthop 2006; 30 (06) 465-472
    CrossrefPubMedGoogle Scholar
  • 91 Pedtke AC, Wustrack RL, Fang AS, Grimer RJ, O'Donnell RJ. Aseptic failure: how does the Compress(®) implant compare to cemented stems?. Clin Orthop Relat Res 2012; 470 (03) 735-742
    CrossrefPubMedGoogle Scholar
  • 92 Gosheger G, Gebert C, Ahrens H, Streitbuerger A, Winkelmann W, Hardes J. Endoprosthetic reconstruction in 250 patients with sarcoma. Clin Orthop Relat Res 2006; 450 (450) 164-171
    CrossrefPubMedGoogle Scholar
  • 93 Bickels J, Wittig JC, Kollender Y. et al. Reconstruction of the extensor mechanism after proximal tibia endoprosthetic replacement. J Arthroplasty 2001; 16 (07) 856-862
    CrossrefPubMedGoogle Scholar
  • 94 D'Adamio S, Cazzato G, Ziranu A, Sgambato A, Rosa MA, Maccauro G. Soft tissue adhesion patterns over Trevira tube on modular endoprosthesis for malignant bone tumours: an in vitro study. J Biol Regul Homeost Agents 2017; 31 (4, Suppl 1): 37-42
    PubMedGoogle Scholar
  • 95 Higuera CA, Inoue N, Lim JS. et al. Tendon reattachment to a metallic implant using an allogenic bone plate augmented with rhOP-1 vs. autogenous cancellous bone and marrow in a canine model. J Orthop Res 2005; 23 (05) 1091-1099
    CrossrefPubMedGoogle Scholar
  • 96 Inoue N, Ikeda K, Aro HT, Frassica FJ, Sim FH, Chao EYS. Biologic tendon fixation to metallic implant augmented with autogenous cancellous bone graft and bone marrow in a canine model. J Orthop Res 2002; 20 (05) 957-966
    CrossrefPubMedGoogle Scholar
  • 97 Mavrogenis AF, Angelini A, Pala E, Sakellariou VI, Ruggieri P, Papagelopoulos PJ. Reconstruction of the extensor mechanism after major knee resection. Orthopedics 2012; 35 (05) e672-e680
    CrossrefPubMedGoogle Scholar
  • 98 Cipriano CA, Dalton J, McDonald DJ. Does patellar tendon repair with gastrocnemius flap augmentation effectively restore active extension after proximal tibial sarcoma resection?. Clin Orthop Relat Res 2019; 477 (03) 584-593
    CrossrefPubMedGoogle Scholar
  • 99 Henderson ER, Pepper AM, Marulanda G, Binitie OT, Cheong D, Letson GD. Outcome of lower-limb preservation with an expandable endoprosthesis after bone tumor resection in children. J Bone Joint Surg Am 2012; 94 (06) 537-547
    CrossrefPubMedGoogle Scholar
  • 100 Monument MJ, Bernthal NM, Bowles AJ, Jones KB, Randall RL. What are the 5-year survivorship outcomes of compressive endoprosthetic osseointegration fixation of the femur?. Clin Orthop Relat Res 2015; 473 (03) 883-890
    CrossrefPubMedGoogle Scholar
  • 101 Ruggieri P, Mavrogenis AF, Pala E, Romantini M, Manfrini M, Mercuri M. Outcome of expandable prostheses in children. J Pediatr Orthop 2013; 33 (03) 244-253
    CrossrefPubMedGoogle Scholar
  • 102 Sambri A, Staals E, Medellin MR. et al. Stanmore noninvasive extendible endoprosthesis in the treatment of bone sarcoma in the preadolescent. J Surg Oncol 2019; 120 (02) 176-182
    CrossrefPubMedGoogle Scholar
  • 103 Picardo NE, Blunn GW, Shekkeris AS. et al. The medium-term results of the Stanmore non-invasive extendible endoprosthesis in the treatment of paediatric bone tumours. J Bone Joint Surg Br 2012; 94 (03) 425-430
    CrossrefPubMedGoogle Scholar
  • 104 Muscolo DL, Ayerza MA, Aponte-Tinao LA, Ranalletta M. Use of distal femoral osteoarticular allografts in limb salvage surgery. J Bone Joint Surg Am 2005; 87 (11) 2449-2455
    PubMedGoogle Scholar
  • 105 Mnaymneh W, Malinin TI, Lackman RD, Hornicek FJ, Ghandur-Mnaymneh L. Massive distal femoral osteoarticular allografts after resection of bone tumors. Clin Orthop Relat Res 1994; (303) 103-115
    PubMedGoogle Scholar
  • 106 Albergo JI, Farfalli GL, Cabas-Geat A, Roitman P, Ayerza MA, Aponte-Tinao LA. Does osteoarticular allograft reconstruction achieve long-term survivorship after en bloc resection of grade 3 giant cell tumor of bone?. Clin Orthop Relat Res 2020; 478 (11) 2562-2570
    CrossrefPubMedGoogle Scholar
  • 107 Wunder JS, Leitch K, Griffin AM, Davis AM, Bell RS. Comparison of two methods of reconstruction for primary malignant tumors at the knee: a sequential cohort study. J Surg Oncol 2001; 77 (02) 89-99 , discussion 100
    CrossrefPubMedGoogle Scholar